ABSTRACT-We studied the antiarrhythmic effects of NS-2 (4-diisobutylamino-1,1-diphenyl-l-butanol maleate) and AFD-19 (active metabolite of NS-2) on early stage ventricular arrhythmias induced by coro nary artery occlusion and reperfusion in anesthetized male rats. These effects were compared with those of disopyramide and mexiletine. Drugs were intravenously administered either before or after coronary occlu sion. When administered 5 min before occlusion, 3 mg/kg of NS-2 and AFD-19 exhibited equivalent anti arrhythmic activity to that of 5 mg/kg of disopyramide and mexiletine, as assessed by reductions in the number of premature ventricular complexes and in the incidences of ventricular tachycardia and ventricular fibrillation. In a dose of 5 mg/kg, the antiarrhythmic effects of NS-2 and AFD-19 were more pronounced. When administered 5 min after coronary artery occlusion, only NS-2 and AFD-19 (in doses of 5 mg/kg) had significant antiarrhythmic effects. None of the drugs influenced the severe ventricular arrhythmias induced by reperfusion when administered 1 min before reperfusion. In conclusion, NS-2 might be effective in reduc ing the severity of the life-threatening ventricular arrhythmias that occur during acute myocardial infarc tion.
NS-2 (4-diisobutylamino-1,1-diphenyl-l-butanol male ate) is a novel class 1 antiarrhythmic agent and AFD-19 (4-isobutylamino-1,1-diphenyl-l-butanol maleate) is an active metabolite of NS-2. Although there seems little doubt that class 1 antiarrhythmic agents are effective against ectopic ventricular beats occurring several hours after onset of myocardial infarction in animal experi ments (1) , there is some controversy concerning their efficacy during the early phase of ventricular arrhythmias; i.e., those occurring during the first 30 min following coronary occlusion (2 8) . This may reflect differences in underlying electrophysiological changes occurring at different stages of ischemia. The time of administration appears to be also important. In this study, the anti arrhythmic effects of NS-2 and AFD-19 were evaluated on the early stage ventricular arrhythmia induced by coro nary artery occlusion and reperfusion in anesthetized rats, and their activity was compared with those of established class 1 drugs, disopyramide and mexiletine. We also evalu ated the difference in the efficacy of each drug when ad ministered either before or after the onset of ischemia and also on reperfusion arrhythmias when administered just prior to reperfusion.
MATERIALS AND METHODS
Male Sprague-Dawley rats (200 300 g) were anesthe tized with 60 mg/kg sodium pentobarbitone administered intraperitoneally. The femoral vein was cannulated for drug administration, and the trachea was cannulated for artificial respiration. Systemic blood pressure was continu ously monitored via a catheter inserted into the carotid artery. A standard limb lead 1 was continuously recorded, together with systemic blood pressure, on a Grass Model 7D recorder (Grass Instrument Co., Quincy, MA, USA). The chest was opened by a left thoracotomy, followed by sectioning of the 4th and 5th ribs, approximately 2 mm to the left of the sternum (9) . Artificial respiration was start ed immediately with room air, using a volume of 2 ml/ 100 g and a rate of 54 strokes/min in order to main tain arterial blood gases and pH within the normal range . After incising the pericardium, the heart was exteriorized using gentle pressure on the rib cage. A 6/0 braided silk suture attached to a 10-mm micropoint reverse cutting needle was placed under the coronary artery. The heart was replaced in the chest, and the rat was allowed to recover for 15 min. Rats that had arrhythmias during the recovery time and/or had a mean arterial blood pressure of less than 70 mmHg were discarded.
All experiments were performed in accordance with the Guidelines for Animal Experiments in Yamanashi Medi cal University.
Studies to determine the effects of disopyramide, mexile tine, NS-2 and AFD-19 on occlusion-induced arrhythmias when administered before coronary occlusion Seventy-eight rats were used in this protocol. Rats were divided into 8 groups with 9 -10 rats in each group. The rats received, by intravenous administration, either saline (n = 10, the vehicle for mexiletine), polyethylene glycol #200 (n=9; the vehicle for disopyramide, NS-2 and AFD 19), disopyramide (5 mg/kg, n=9), mexiletine (5 mg/kg, n = 10), NS-2 (either 3 or 5 mg/kg, n = 10 and 10) or AFD-19 (3 or 5 mg/kg, n= 10 and 10). The injection volume of each agent was adjusted to 0.5 ml with saline. Coronary ligation was commenced 5 min after drug ad ministration, and the electrocardiogram and systemic ar terial blood pressure were continuously recorded for 30 min after coronary ligation. Blood pressure and sinus rate were measured before injection; at 1 min, 3 min, 5 min after injection; and at 1 min, 5 min, 10 min, 15 min and 30 min after coronary artery occlusion.
Studies to determine the effects of disopyramide, mexile tine, NS-2 and AFD-19 on occlusion-induced arrhythmias when administered after coronary occlusion Eighty-two rats were used in this protocol. Drugs and the doses were the same as above. The number of rats in each group was 10, except for group 1 (saline control) where 12 rats were used. Each drug was administered 5 min after coronary occlusion. The electrocardiogram and systemic arterial blood pressure were continuously record ed for 30 min after coronary occlusion. Blood pressure and sinus rate were estimated before occlusion and at 1 min and 5 min after occlusion (before injection), 6 min af ter occlusion (1 min after injection), 8 min after occlusion (3 min after injection), 10 min after occlusion (5 min after injection), 15 min after occlusion (10 min after injection) and 30 min after occlusion (25 min after injection).
Studies to determine the effects of disopyramide, mexile tine, NS-2 and AFD-19 on reperfusion arrhythmia Both ends of the ligature placed under the left coronary artery were passed through a small plastic tube. Regional myocardial ischemia could be induced by pulling the su ture and pressing the tube against the surface of the myo cardium. The ischemia could be maintained for any desired period by clamping the tube and the suture. Reper fusion could be initiated by declamping and removing the tube.
We first evaluated the relationship between occlusion time (i.e., the duration of ischemia) and the severity of the arrhythmias resulting from reperfusion, and we ulti mately used 6 min of occlusion time to determine the effects of each drug on reperfusion-induced arrhythmias. The doses of drugs were the same as above. Each drug was administered at 5 min after coronary occlusion (1 min before reperfusion). The electrocardiogram and sys temic arterial blood pressure were recorded continuously for 20 min after reperfusion.
Assessment of arrhythmias
The total number of premature ventricular complexes (PVC), incidence of ventricular tachycardia (VT), inci dence of ventricular fibrillation (Vf) and mortality rate during 30 min after coronary occlusion in occlusion ar rhythmias and during 20 min after reperfusion in reper fusion arrhythmias were assessed in comparison with a con trol group. Vf is not necessarily a terminal event in this model. The values are expressed as the mean ±standard error. Changes within each group were compared by the paired Student's t-test, whereas differences between groups were assessed by the Mann-Whitney U-test. Changes in inci dences of events were analyzed by Fisher's exact probabil ity test. Differences were regarded as significant if the P values were less than 0.05.
All drugs were kindly supplied by Nippon Shinyaku Co., Ltd. (Kyoto).
RESULTS
The effects of disopyramide, mexiletine, NS-2 and AFD 19 on occlusion arrhythmias when administered before coronary artery occlusion
In this model, premature ventricular activity com mences at 4 min after the onset of ischemia, with pro nounced activity over the next 10 min (mainly as VT), and this is then followed by a period of arrhythmic silence with only a few ventricular complexes (Fig. 1) . Effects of class 1 antiarrhythmic drugs on the ischemia-induced ar rhythmias are summarized in Fig. 2 . There were no sig nificant differences between the arrhythmias in the saline control group and polyethylene glycol #200 (PEG #200) vehicle control group with respect to the total number of PVC, incidences of VT, incidences of Vf or in mortality rate (10% in the saline group, 33% in the polyethylene glycol group). The total numbers of PVC in the con trol groups were 1185 ± 158 beats (saline) and 1160-h 163 beats (PEG #200). Although disopyramide and mexiletine decreased the total numbers of PVC to 632±204 beats and 696±226 beats, respectively, these differences were not significant. Even 3 mg/kg of NS-2 and AFD-19 sig nificantly decreased the total numbers of PVC. A 5 mg/kg dose of NS-2 and AFD-19 was more effective. The total numbers of PVC were 682-- Incidences of Vf were 60%, 56%, 10% (P <0.05 vs. control), 10% (P <0.05 vs. control), 10% (P < 0.05 vs. control), 20%, 0% (P < 0.01 vs. control) and 0% (P<0.01 vs. control), respectively. AFD-19 was rather more effective than NS-2. Arrhythmic death was completely abolished by an antiarrhythmic drug.
Effects of disopyramide, mexiletine, NS-2 and AFD-19 on occlusion arrhythmias when administered after coronary occlusion Figure 3 shows the effects of drugs administered after occlusion. In contrast to the pretreatment, antiar rhythmic effects were attenuated when drugs were ad ministered after occlusion. Only 5 mg/kg of NS-2 and AFD-19 significantly decreased the total numbers of PVC. None of the drugs reduced the incidence of the more serious ventricular arrhythmias (VT, Vf) or mortal ity (mortality in the mexiletine group, 20% vs. saline con trol 20%; mortality in the disopyramide, NS-2 and AFD 19 group, 10-20% vs. PEG #200 control, 10%). 
Hemodynamic effects of disopyramide, mexiletine, NS-2 and AFD-19 when administered before and after coro nary artery occlusion
The results are summarized in Figs. 4 and 5. The vehi cles slightly decreased the heart rate and increased the mean arterial blood pressure. When administered before coronary occlusion, disopyramide decreased the heart rate from 423 ±23 to 3344:15 beats/min (P<0.01) and in creased the mean arterial blood pressure from 81:i--3 to 105 ± 7 mmHg (P < 0.01), whereas mexiletine decreased the heart rate from 447±I0 to 365 ± 14 beats/min (P < 0.01), but did not affect the arterial blood pressure. NS-2 significantly decreased both the heart rate and the blood pressure in a dose-dependent manner, whereas AFD-19 decreased the heart rate from 467±14 to 376±11 beats/min (P<0.01) at the dose of 3 mg/kg and from 433 ± 16 to 357± 17 beats/min (P <0.01) at the dose of 5 mg/kg, but did not influence the blood pressure. The hemodynamic changes induced by coronary artery occlu sion were similar in all groups; there was a slight increase in the heart rate and a significant decrease in the blood pressure with some recovery over the 30-min occlusion period.
The hemodynamic effects of drugs administered after coronary artery occlusion are summarized in Fig. 5 . Disopyramide significantly reduced the heart rate from 443-L23 to 343 4:17 beats /min (P<0.01), but did not affect the mean blood pressure. Mexiletine significantly reduced both the heart rate from 461 ±23 to 359±23 beats/min (P<0.01) and the mean blood pressure from 78±6 to 62±4mmHg (P<0.01).
NS-2 and AFD-19
decreased the sinus rate and the mean blood pressure in a dose-response manner. Compared with the hemodynamic effects of drugs administered before occlusion, mexiletine and AFD-19 decreased the mean blood pressure, and the increase in blood pressure by disopyramide was attenuat ed, but decreases in the heart rate were accentuated. Effects of disopyramide, mexiletine, NS-2 and AFD-19 on reperfusion arrhythmias when administered 1 min prior to the onset of reperfusion The severity of reperfusion arrhythmias depends on the duration of the preceding ischemic period (10, 11) . Few ar rhythmias occur following periods of 1 or 3 min of ische mia, but there is pronounced ectopic activity with a high incidence of Vf, most of it might be terminal, when the myocardium is reperfused following the 5-min occlusion periods ( Table 1 ). The severity of arrhythmias following 6-min occlusion was similar.
None of the drugs significantly influenced the severity of reperfusion arrhythmias when administered 1 min prior to the onset of reperfusion (Table 2) . Antiarrhythmic agents effective under the ischemic con dition are thought to act by altering the duration of the refractoriness, by modifying the conduction velocity and the degree of the inhomogeneity (13) . From the experi ments using normal guinea pig papillary muscles, Kojima and Ban (14) demonstrated that there are two phases in the recovery process of Vm, the early recovery phase hav ing a time constant of 10 30 msec and the late recovery phase with a time constant of 2 3 sec. The recovery time constants (2-3 sec) for AFD-19 and NS-2 were similar to that of procainamide (class la), greater than those of lidocaine and mexiletine (class lb) and smaller than that of flecainide (class 1c). NS-2 is reported to have a high affinity for inactivated channels with an intermediate recovery time constant, whereas AFD-19 is suggested to have a higher affinity for open channels and an inter mediate recovery time constant. When NS-2 is administer ed systemically, it would be expected to have a unique pro file of antiarrhythmic activity with a combined effect on inactivated sodium channels (the parent compound) and on open sodium channels (the active metabolite). In spite of these apparent differences, the effects of NS-2, AFD 19, disopyramide and mexiletine on coronary artery oc clusion-induced arrhythmias were almost the same. A decrease in conduction velocity may play the most im portant role in suppressing coronary occlusion-induced arrhythmias in rats. Early stage ventricular arrhythmia induced by myocardial ischemia is reported to be related to the extracellular potassium concentration (15) , cyclic AMP (16) and prostaglandins (17) . Mapping studies rev eal that ischemia-induced arrhythmia in dogs might be induced by reentrant mechanisms and that the impulse travels through the ischemic area surrounding the infarcted area (13) . The reentrant mechanism needs a dual path way, unidirectional block, and conduction delay. Almost all class 1 antiarrhythmic agents decrease the conduction velocity and some of them have effects to elongate the ac tion potential duration. So these agents might block one reentrant circuit, but might set up another reentrant cir cuit. When drugs are administered before occlusion, the distribution of drugs would be uniform. However, the tis sue concentration of drugs administered after occlusion must be lower in the hypoperfused ischemic area than in normoperfusion area, especially in a species such as the rat which has a very poor coronary collateral circulation. This imbalance in the tissue distribution might intensify the electrical inhomogeneity that results from myocardial ischemia, and this may be the main reason why when the drugs are administered after occlusion, they are not effec tive against early ischemic arrhythmias; and, indeed, some aggravate them. Moreover, the administration of drugs after coronary occlusion usually lowers blood pres sure, and hence presumably decreases coronary perfu sion.
In the clinical situation, there are few opportunities to administer antiarrhythmic agents before the onset of myo cardial infarction, although it has been recommended that lidocaine should be given as soon as a ventricular ar rhythmia is documented after myocardial infarction (18) . Many studies have confirmed the effectiveness of drugs in the treatment of arrhythmias in the coronary care unit; i.e., on the later stages of acute myocardial infarction, but there are few studies in the very early stages of acute myocardial infarction. There are several reasons for this.
The first reason is a high mortality rate in the first two hours after the onset of an acute coronary attack. The rate of mortality rapidly declines after then. The second reason is that acute myocardial infarction occurs in the large majority of patients outside of hospitals. Pantridge (19) reported that only 16% of patients reach the hospital within 4 hr of the onset of symptoms, a figure that has not been greatly improved upon over the succeeding 20 years.
Our results indicate that class 1 antiarrhythmic agents administered after coronary occlusion are less effective against early stage arrhythmias of myocardial infarction than those administered prior to occlusion in anesthetized rats. Moreover, the administration of drugs after occlu sion lowered the blood pressure, which might result in a decrease in myocardial perfusion. They did not modify reperfusion-induced arrhythmias if given just prior to the onset of reperfusion. However, as described before, AFD-19 is an active metabolite of NS-2 and has different sodium channel blocking properties from those of NS-2. Therefore, NS-2 given orally before the onset of acute myocardial infarction is expected to be more effective. The combination therapy of different types of class 1 anti arrhythmic agents has already been reported to have a beneficial effect in a clinical study (20) .
